Randomized Phase II Trial of Bevacizumab plus Everolimus versus Bevacizumab Alone for Recurrent or Persistent Ovarian, Fallopian Tube or Peritoneal Carcinoma: an NRG Oncology/Gynecologic Oncology Group Study

PURPOSE: Bevacizumab (BV) monotherapy leads to compensatory upregulation of multiple signaling pathways, resulting in mTOR activation. We evaluated combining BV and everolimus (EV), an mTOR kinase inhibitor, to circumvent BV-resistance in women with recurrent or persistent ovarian, fallopian tube or...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Gynecol Oncol
Main Authors: Tew, William P., Sill, Michael W., Walker, Joan L., Secord, Angeles Alvarez, Bonebrake, Albert J., Schilder, Jeanne M., Stuckey, Ashley, Rice, Laurel, Tewari, Krishnansu S., Aghajanian, Carol A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6350932/
https://ncbi.nlm.nih.gov/pubmed/30177462
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2018.08.027
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados